Summary

The present study was conducted to compare the influence of amlodipine, ramipril and losartan on cardiovascular outcomes in patients with metabolic syndrome, complicated by the chronic kidney disease. Our study showed, that ramipril and losartan were more effective at regression of left ventricle hypertrophy and changing profile of blood pressure than amlodipine. Even so, losartan was more effective in patients with «full» (or ״complete״) metabolic syndrome than ramipril and amlodipine.